Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Crestor/ABT-335 combination: Phase III started

The companies began the 12-week, double-blind, U.S. Phase III M06-844 trial in 675 patients

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE